Search hospitals > Connecticut > West Haven

VA Connecticut Healthcare System

Claim this profile
West Haven, Connecticut 06516
Global Leader in Lung Cancer
Global Leader in Alcoholism
Conducts research for Post-Traumatic Stress Disorder
Conducts research for Cancer
Conducts research for Schizophrenia
280 reported clinical trials
32 medical researchers
Photo of VA Connecticut Healthcare System in West HavenPhoto of VA Connecticut Healthcare System in West HavenPhoto of VA Connecticut Healthcare System in West Haven

Summary

VA Connecticut Healthcare System is a medical facility located in West Haven, Connecticut. This center is recognized for care of Lung Cancer, Alcoholism, Post-Traumatic Stress Disorder, Cancer, Schizophrenia and other specialties. VA Connecticut Healthcare System is involved with conducting 280 clinical trials across 389 conditions. There are 32 research doctors associated with this hospital, such as Herta H. Chao, Mohini Ranganathan, MD, Deepak C. D'Souza, M.D., and Joao P. De Aquino, M.D..

Area of expertise

1Lung Cancer
Global Leader
VA Connecticut Healthcare System has run 28 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Alcoholism
Global Leader
VA Connecticut Healthcare System has run 27 trials for Alcoholism.

Top PIs

Clinical Trials running at VA Connecticut Healthcare System

Non-Small Cell Lung Cancer
Lung Cancer
Prostate Cancer
Post-Traumatic Stress Disorder
Substance Use Disorders
Opioid Use Disorder
Cancer
Small Cell Lung Cancer
Chronic Pain
Deep Vein Thrombosis
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Sotorasib

for Non-Small Cell Lung Cancer

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Recruiting2 awards Phase 219 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at VA Connecticut Healthcare System?
VA Connecticut Healthcare System is a medical facility located in West Haven, Connecticut. This center is recognized for care of Lung Cancer, Alcoholism, Post-Traumatic Stress Disorder, Cancer, Schizophrenia and other specialties. VA Connecticut Healthcare System is involved with conducting 280 clinical trials across 389 conditions. There are 32 research doctors associated with this hospital, such as Herta H. Chao, Mohini Ranganathan, MD, Deepak C. D'Souza, M.D., and Joao P. De Aquino, M.D..